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Purpose of the study
To assess the therapeutic effectiveness of a strategy of
induction with enfuvirtide (T20) within an optimised reg-
imen of antiretroviral drugs (ARV) in patients infected
with HIV-1 in routine clinical practice carried out in differ-
ent hospitals in Spain.
Methods
We performed a retrospective multicenter study to evalu-
ate efficacy of induction with T20. Induction strategy was
defined as use of T20 in a salvage regimen for a limited
period of time (without switching to another active drug).
We considered "responders" as all patients who had VL
<50 before stopping T20. Six months after stopping T20
we considered "rebounders" as all patients who had VL >
50 and "non-rebounders" as those who maintained VL
<50. We explored risk factors for virological rebound after
stopping T20.
Summary of results
62 patients included (16 women) from 10 hospitals,
mean age 43 years, median time since HIV diagnosis: 16
years. 43% CDC C3. Before starting salvage regimen,
median CD4 count was 154 cells and median VL was 4.2
log. Patients had had six previous ARV regimens on aver-
age. Genotyping showed M184V in 57.4%, K103N in
34.4%, TAMs in 72.1%, and 41% had at least five PI muta-
tions. Patients received T20 for a median of 9.3 months
(1.2–34.3).
Forty-one patients (66.1%) were responders. Of these 41
patients, 37 (90.2%) were non-rebounders. The salvage
regimen in non-rebounders contained: TDF and FTC
(59%), LPV/r (35%) DRV/r (21.6%), TPV/r (18.9%),
SQV/r (10.8%) and ATV/r (one pt), FOS-APV/r (one pt),
RAL (8.1%) and MVC (one pt). Rebounders were treated
with TDF and FTC (75%), TPV/r (two pts), LPV/r (one pt)
and FAM/r (one pt). No significant differences were
found.
Conclusion
In contrast with prior studies, the majority of patients who
achieved viral suppression after starting T20 maintained
suppression after stopping it. This is probably related to
the higher antiviral activity of the background regimen.
(Table 1.)
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Rebounder n = 4 Non-Rebounder n = 37
Major PI mutations (median) 6 3
DRV or RAL or MVC in the regimen 0 (0%) 7 (19%)
TPV in the regimen 2 (50%) 7 (18,9%)
Total Time on T20 (median, months) 17,8 7Page 2 of 2
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